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Introduction: The identification of key pathways dysregulated in
non-small cell lung cancer (NSCLC) is an important step toward
understanding lung pathogenesis and developing new therapeutic
approaches.
Methods: Toward this goal, reverse-phase protein lysate arrays
(RPPA) were used to compare signaling pathways between NSCLC
tumors and paired normal lung tissue from 46 patients and assess
their association with clinical outcome.
Results: After RPPA quantification of 63 proteins and phosphopro-
teins, tissue pairs were randomized to a training set (n  25 pairs)
and test set (n  21 pairs). In the training set, 15 protein markers
were differentially expressed between tumors and normal lung (p 
0.01), including markers in the PI3K/AKT and p38 MAPK signaling
pathways (e.g., p70S6K, S6, p38, and phospho-p38), as well as
caveolin-1 and -catenin. A four-protein signature (p70S6K, cyclin
B1, pSrc(Y527), and caveolin-1) independent of histology classified
specimens as tumor versus normal with a predicted accuracy of
83%, sensitivity of 67%, and specificity of 100%. The signature was
validated in the test set, correctly classifying all normal tissues and
14 of 21 tumor tissues. RPPA results were confirmed by immuno-
histochemistry for caveolin-1 and p70S6K. In tumors from patients
with resected NSCLC, expression of proteins in the energy-sensing
AMPK pathway (pLKB1, AMPK, p-Acetyl-CoA, pTSC2), adhe-
sion, EGFR, and Rb signaling pathways was inversely associated
with NSCLC recurrence.
Conclusions: These data provide evidence for dysregulation of
several pathways including those involving energy sensing and
adhesion that are potentially associated with NSCLC pathogenesis
and disease recurrence.
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Lung cancer is the leading cause of cancer death in theUnited States, with a 5-year overall survival of 16% for all
stages.1 Although chemotherapy is the standard treatment for
advanced or metastatic non-small cell lung cancer (NSCLC),
overall response rates do not exceed 20 to 30% with current
front-line therapy.1–3 Newer targeted agents show promise in
combination with traditional cytotoxic chemotherapy but still
only benefit a small subset of biologically susceptible pa-
tients. Therefore, a better understanding of the signaling
pathways that are dysregulated in NSCLC has the potential to
contribute to improved outcomes.
Defects in cell signaling pathways play a critical role in
cancer cell growth, survival, invasion, and metastasis. An
important goal of proteomics is to provide a map of the
signaling pathways that are dysregulated in tumor cells as
compared with normal cells. These aberrations could identify
novel predictors of response or identify novel targets for
therapy. Protein profiling is an important complement to
other molecular profiling techniques such as gene expression
analysis because proteins are the immediate effector mole-
cules and, unlike transcriptional profiling, protein profiling
can quantify post-translational modifications (e.g., phosphor-
ylation status) that are intimately linked with activation of
signaling proteins such as the receptor tyrosine kinases. In
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addition, protein profiling directly characterizes potential
drug targets and provides potential predictive markers, be-
cause most drugs act directly on protein function.
To date, only a few studies report the use of proteomic
technologies to assess protein expression in lung tumors.
Several groups have used matrix-assisted laser desorption
ionization mass spectrometry4,5 or electrospray ionization
mass spectrometry, often in combination with 2D gel elec-
trophoresis, of a small number of samples to identify poten-
tial tumor markers in lung cancers including cytokeratins,
annexin II, cathepsin D, HSP27, stathmin, and MnSOD.5
Matrix-assisted laser desorption ionization time-of-flight was
also shown to distinguish tumor tissues from normal, deriving
a 25-signal proteomic signature associated with poor out-
come.6–8 However, mass spectrometry technology is not
widely used in clinical applications because of the large
volume of sample required, relatively low throughput, high
cost, and relative lack of sensitivity in detecting low-abun-
dance proteins important for cellular functions.
In this study, we compare key signaling proteins from
prosurvival, mitogenic, apoptotic, and growth regulatory
pathways between paired NSCLC tumor and normal lung
specimens using reverse-phase protein array (RPPA). RPPA
is a quantitative, high-throughput assay that allows broad and
simultaneous profiling of therapeutically relevant signaling
networks.9–11 The technique has been successfully used in
other malignancies such as breast cancer to identify signaling
pathway abnormalities, pharmacodynamic markers, and pro-
teins associated with therapeutic resistance.12–14
In this report, we show that 15 proteins were signifi-
cantly differentially expressed between normal lung and
NSCLC tumors, including those involved in cell scaffolding,
PI3K/AKT, and MAPK signaling. Among these, we found a
four-protein signature (caveolin-1, p70S6K, cyclin B1, and
pSrc(527)) able to distinguish tumors from normal lung.
These findings were then validated in an independent set of
paired tumors, and results for caveolin-1, cyclin B1, and
p70S6K were confirmed by immunohistochemistry (IHC). In
addition, protein expression analysis identified an association
between tumor recurrence and alterations in the energy sens-
ing AMPK pathway, adhesion pathways, EGFR pathway, and
Rb (total and phosphorylated) levels. These results suggest
that a 4-marker signature can aid in the diagnosis of NSCLC
as well as point to potential targets for NSCLC treatment.
RESULTS
Proteomic Markers Differentiate NSCLC
Tumors from Normal Lung
Sixty-three proteins and phosphoproteins were selected
for analysis based on their involvement in key signaling
pathways or cellular functions, including the (1) PI3K path-
way, (2) MAPK pathway, (3) LKB1 pathway, (4) JAK/STAT
pathway, (5) apoptosis, (6) cell polarity, (7) tyrosine kinase
pathways including EGFR, (8) nuclear receptor pathway, and
(9) cell cycle regulation. Protein markers were quantified by
RPPA in 46 paired tumor and normal tissues from resected
lung specimens.
Forty percent of the patient samples were arrayed in
duplicate in different areas of each slide to assess reproducibil-
ity. For each protein, the Pearson correlation between duplicate
samples was calculated. The median correlation coefficient
across all protein markers was 0.734 (corresponding to a p value
of 3.0  105). Duplicate samples were then averaged and
unsupervised hierarchical clustering performed for all patient
specimens with all 63 RPPA markers. Clustering demonstrated
a clear division between normal lung and tumor specimens
(Figure 1). Reproducibility for individual proteins quantified by
RPPA was validated by the clustering of repeat antibody stain-
ing such as phospho-p38, pLKB1, and cyclin D1 being nearest
neighbors on unsupervised hierarchical clustering (Figure 1).
To further analyze specific factors most strongly dis-
tinguishing normal lung from NSCLC, paired samples were
then randomly divided into a training set (n  25 pairs) and
test set (n 21 pairs) for further analysis. Among the training
set, using a conservative cutoff to account for multiple testing
(false discovery rate [FDR] 1%, corresponding to a p value
0.005), 15 markers were expressed at significantly different
levels in tumor and normal tissue by two-sample t test (Table
1, Figure 2). Several of these markers reflected changes in the
PI3K/AKT and p38 MAPK signaling pathways. For example,
total Akt (p  0.002) was increased in tumors relative to
normal lung tissue, as were total and phospho-p38 (p 9.9
105 and 0.003, respectively), PAI1 (p  1.87  105), and
p70S6Kinase and S6 (p  9.3  106 and 0.0014, respec-
tively). Compared with normal tissue, tumors also demon-
strated a decrease in the scaffolding protein caveolin and in
-catenin. Src pathway activity was elevated in tumors, as
reflected by decreased phosphorylation of the autoinhibitory
site pSrc(Y527), as previously described.15
Although total Akt decreased in tumors compared with
normal lung, the level of pAkt T308 relative to total Akt
increased significantly (p  0.0004) (Figure 2B), suggesting
a shift toward Akt pathway activation in tumors. Similarly,
the decrease in total FAK noted in tumor samples was
associated with a relative increase in pFAK Y576 (p 
2.67  105) and pFAK Y397 (0.008) (Figure 2B). Because
FAK is a downstream target of Src, this observation is
consistent with increased activity of the Src pathway in
NSCLC tumors, as reflected by decreased phosphorylation of
the autoinhibitory Src site (pSrc(Y527)). Of note, tumors
were well balanced in histology between adenocarcinomas
(n 24) and squamous cell carcinomas (n 22), and among
the 15 markers differing between normal and tumor tissue,
only PAI1 was also differentially expressed between histol-
ogies (higher in squamous cell carcinomas, p  0.0044).
Four-Marker Signature Differentiates NSCLC
from Normal Lung
We then tested whether a marker set of proteins differ-
entially expressed between tumor and lung could be identified
that could correctly classify an independent set of samples.
To determine the optimal number of markers to be combined,
we computed the sensitivity, specificity, positive predictive
value, and negative predictive value for combining the top 2
up to the top 10 markers. The top four markers (caveolin-1,
pSrc(Y527), cyclin B1, and p70S6K) were selected for the
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model because they resulted in a predicted accuracy of 0.833,
sensitivity of 0.667, specificity of 1.000, positive predictive
value of 1.000, and negative predictive value of 0.750, which
was superior to using only the top 2 to 3 markers and was as
good as the predictions for the top 5 to 10 markers (Supple-
mental Table 3, http://links.lww.com/JTO/A36).
Validation of the Four-Marker NSCLC
Signature
The ability of the four-marker signature to classify
tumor versus normal lung tissue was then tested by diagonal
linear discriminant analysis. In the training set, the signature
correctly classified all 25 normal samples and 22 of 25 tumor
samples (Figure 3A). The four markers were then used to
classify the 21 paired samples in the test set. In this set, all
normal samples and 14 of 21 tumor samples were correctly
classified (Figure 3B). The receiver operating characteristic
plot demonstrates good performance of the model, with an
area under the curve of 0.961  0.031 (Figure 3C).
Validation of RPPA Protein Markers by IHC in
Paraffin-Embedded Samples
Of the four markers in the NSCLC signature, antibodies
optimized to detect caveolin-1, p70S6K, and cyclin B1 in
paraffin-embedded samples by IHC were available for vali-
dation of the RPPA results. Caveolin-1, p70S6K, and cyclin
FIGURE 1. Unsupervised hierarchical clustering identifies distinct protein expression patterns between normal lung and non-
small cell lung cancer (NSCLC) tumors. Levels of 63 proteins and phosphoproteins were determined by reverse-phase protein
lysate arrays in paired normal lung (blue) and NSCLC (red) samples from 46 patients. Unsupervised hierarchical clustering
separated samples into two main groups based on differences in protein expression. One group contained a majority of the
tumor samples (red), whereas the other contained mostly normal lung (blue), indicating major differences in protein expres-
sion between tumor and normal lung, even within an individual patient. Replicate proteins, such as p-p38(T180), pLKB1, and
cyclin D1, clustered next to each other.
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B1 levels were quantified by IHC in formalin-fixed paraffin-
embedded (FFPE) tissue in 39 of the 46 paired normal and
tumor samples and compared with levels in the stroma,
alveoli, and bronchial epithelium using paired t tests. Expres-
sion levels were scored as the percentage of tumor cells
staining positive (0–100%) times the intensity of staining (0
through 3), giving a possible range of IHC levels from 0 to
300. Tumor cell and alveolar stroma staining was success-
fully scored in all 39 samples. One patient specimen could
not be scored for alveoli staining because of insufficient
tissue, and 14 lacked sufficient tissue for bronchial epithelial
staining. IHC scores are shown in Supplemental Table 4
(http://links.lww.com/JTO/A36).
Consistent with the results observed by RPPA, caveolin-1
levels were highest in normal alveolar stromal tissue, which was
15-fold higher than levels measured in tumor cytoplasm (median
in alveolar stroma 300 versus median in tumor cytoplasm 20.0,
p  2.2  1016) and 30-fold higher than in tumor membrane
(median in tumor membrane 10.0, p  2.2  1016) (Table 2).
Caveolin-1 levels in membrane of normal alveoli were also
significantly higher than those of tumor membrane (eight-fold
higher in alveoli, p  0.013). Although basal cells in the
bronchial epithelium expressed high levels of caveolin-1 by
IHC, expression was low in other strata of bronchial epithelium,
resulting in an overall low IHC score among bronchial epithelial
cells compared with other tissues.
Levels of p70S6K and cyclin B1 were then quantified in
cytoplasm from tumor tissue, normal alveoli, and bronchial
epithelial. Consistent with the RPPA measurements, p70S6K
and cyclin B1 were significantly higher in tumor as compared
with alveoli (p 1.24 1013 and 4.18 106, respectively).
The median level of p70S6K in patient tumors was 60.0. In
contrast, p70S6Kwas not detected in any normal alveoli sample.
Tumors also had higher levels of p70S6K compared to bronchial
epithelium (median in tumor 60.0, median in bronchial epithelium
50.0, p 0.039). No cyclin B1 was detectable in any normal tissue
sample (alveoli or bronchial epithelium). Cyclin B1 levels ranged
from 0 to 210 in tumor samples (median 20.0) (Table 2).
Correlation of RPPA Markers with
Clinicopathological Features Identifies Lower
Tumor pAMPK in Current Smokers
Using data from all 46 patients, tumor levels of each
protein were then correlated with clinicopathological features
and outcome data. For each patient, the protein levels in the
tumor specimens were first normalized using the paired normal
lung tissue and then compared between clinical groups by t test
or analysis of variance (ANOVA). None of the protein markers
were significantly associated with age, gender, overall stage
(I–IV), T stage, or N stage. To analyze the possible interaction
between smoking status and protein expression, current smokers
(n  22) were compared with former smokers (n  22).
Phospho-AMPK was lower in current smokers, as compared
with former smokers (median in current smokers 0.968, me-
dian in former smokers 0.605, p  0.001). None of the RPPA
markers were significantly different in normal lung tissue be-
tween current and former smokers.
NSCLC Recurrence Associated with Decreased
AMPK Pathway Proteins, Adhesion Markers,
and Total and Phospho-Rb
Protein markers were then compared between patients
with (n  19) and without (n  27) NSCLC recurrence by
ANOVA. At a FDR of 30% (corresponding p 0.019), six
TABLE 1. Proteins and Phosphoproteins Differentially Expressed Between Normal Lung
and NSCLC
Protein Marker
Mean of Normal
Lung (log 2)
Mean of
Tumor (log 2)
Difference
(log 2) T Score p
Adhesion/invasion
Caveolin 8.79 5.03 3.76 8.43 5.04E-11
pSrc(Y527) 2.30 0.01 2.29 5.97 2.80E-07
PAI1 3.75 1.85 1.90 4.75 1.87E-05
Paxillin 4.54 3.46 1.08 4.65 2.63E-05
FAK 3.29 2.20 1.09 3.35 0.002
-catenin 3.88 3.00 0.88 3.09 0.003
PI3K/Akt pathway
p70s6kinase 1.79 2.65 0.86 4.96 9.25E-06
S6 4.64 3.73 0.91 3.39 0.001
AKT 2.67 1.88 0.79 3.29 0.002
P38 MAPK/ERK
p38 0.46 1.19 0.73 4.25 9.93E-05
p38 p180 0.24 0.91 1.16 3.10 0.003
Other
Cyclin B1 3.36 0.68 2.68 6.38 6.67E-08
SMN 2.03 2.64 0.60 3.11 0.003
Src3/AIB1 1.02 0.35 0.67 4.85 1.33E-05
Gemin3 0.75 0.37 0.38 2.92 0.005
Protein abbreviations listed in Supplemental Table 2.
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markers were significantly different between patients with and
without recurrence. At an FDR of 50%, seven additional mark-
ers that were associated with recurrence were identified (p 
0.066–0.119) (Table 3). Patients with recurrence had downregu-
lation of markers in the AMPK signaling pathway, as indicated
by decreased levels of total AMPK and pTSC2 and increased
acetyl-CoA (normally inhibited by AMPK). pLKB1, an up-
stream activator of AMPK, was also higher in patients without
recurrence, although this did not reach statistical significance.
Recurrence was also associated with a trend toward
lower levels of adhesion-associated molecules paxillin (both
total and phosphorylated), p-p130 Cas, and STAT3. Lower
levels of EGFR pathway signaling components (total EGFR,
pAKT(T308), and ERK2) and Rb (total and phosphorylated)
were also associated with recurrence.
The difference in RPPA markers in patients with and
without recurrence was also analyzed by stage. As expected,
recurrences were more common in patients with higher stage
disease (recurrences in 8/20 stage I patients, 4/15 stage II, 5/9
stage III, and 2/2 stage IV). Because of the small number of
patients, those with stage I/II and III/IV were grouped for
analysis. No RPPA markers were significantly different in stage
I/II patients with and without recurrence. However, in stage
III/IV patients, three markers were significantly different at an
FDR of 40% (p  0.008) and nine markers at an FDR of 50%
(p  0.05). Five of these nine markers were the same as in the
analysis of all stages together, including AMPK pathway mark-
ers (total AMPK, pTSC2, and ACoA), EGFR, and Rb. Two
additional markers also in the AMPK pathway that were iden-
tified by the analysis of stage III/IV patients were downstream
targets of TSC2, pS6(Y240), and pS6(Y235). The two markers
not seen in the previous analysis of all stages together were p21
and cMyc, both lower in patients with recurrence.
Improved Cause-Specific Survival Associated
with Elevated pTSC2
The association between cause-specific survival and
protein markers was also analyzed. At an FDR of 30%
FIGURE 2. Identification of proteins differentially
expressed between paired normal lung and non-
small cell lung cancer tumor samples. A, Protein
and phosphoprotein levels for 63 markers were
compared between normal tissue (blue) and tu-
mor tissue (red) from patients who underwent
surgical resection of their tumors. Protein levels
were compared between the two groups by t test
and those with p value 0.005 (false discovery
rate 1%) are shown. B, The ratio of phospho- to
total protein levels are shown for Akt and FAK.
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(corresponding p  0.0064), pTSC2 was again noted to be
a favorable prognostic marker (p  0.00012) with higher
levels in patients who were either alive at the end of the
study or censored based on death from a non-NSCLC–
related cause. ERK2 was also associated with longer
cause-specific survival (p  0.012, corresponding FDR
50%). No protein markers were associated with overall
survival. However, this analysis was limited by the high
number of deaths among patients without disease recur-
rence (9/27 patients). When cause-specific survival was
analyzed by stage, no markers were associated with shorter
survival in patients with stage I/II disease. However, in
stage III/IV patients, downregulation of pLKB1, an up-
stream activator of AMPK, and pS6(Y235) were signifi-
cantly associated with shorter cause-specific survival.
There was a trend toward improved outcome with higher
levels of paxillin (total and phospho), p-p130 Cas, STAT3,
and pAkt in stage III/IV patients, although this did not
reach significance (p  0.07–0.19).
DISCUSSION
RPPA was used to assess the protein levels and activation
status of signal transduction pathways implicated in lung can-
cers. We analyzed 46 paired tumors and matched normal tissue
to identify differences in protein expression between these tis-
sues. Compared with their paired normal lung samples, tumors
expressed lower levels of caveolin-1 and -catenin, increased
invasion markers (e.g., PAI1), and higher levels of PI3K/AKT
and p38 MAPK pathway components. Although a large number
FIGURE 3. A four-marker proteomic signature discriminates tumor from normal lung tissue. A, The receiver operating charac-
teristic curve shows good performance of the model to correctly classify tumor and normal tissues. B, Two-way hierarchical
clustering of the normal (blue) and tumor (red) tissues from the training set shows that these tissues are well differentiated by
levels of the four markers (p70S6K, cyclin B1, pSrc(Y527), and caveolin). C, Similarly, the four markers also separate normal
(blue) from tumor (red) in the test set.
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of proteins and phosphoproteins were differentially expressed in
tumor versus normal tissues, a signature of only four markers
was sufficiently robust to distinguish normal lung from tumor in
our test set, suggesting that these proteins contain significant
information content. These discriminators were p70S6K, cyclin
B1, pSrc(Y527), and caveolin-1. Of note, these four markers
were not associated with histology or smoking status.
Among the four markers in the NSCLC signature, caveo-
lin-1 (decreased in tumor tissue) is a scaffolding protein present
in plasma membrane caveolae microdomains rich in signaling
molecules.16 Caveolin-1 has previously been shown to be a
tumor suppressor that is downregulated in lung cancer cell lines
relative to normal bronchial epithelial cells,16 and its expression
differs by tumor stage and tumor type.17,18 In addition, we also
observed reduced levels of -catenin relative to normal lung.
-catenin, which associates with caveolin-1, may be associated
with malignant transformation19 and progression of pulmonary
adenocarcinoma.19 Because caveolin-1 can stabilize -catenin,
reduced caveolin-1 levels promote -catenin degradation.20
We then correlated protein levels in resected tumors with
clinical outcomes. In this analysis, we observed an association
between elevated expression of proteins in the energy-sensing
AMPK pathway and decreased recurrence, longer cause-specific
survival, and smoking status. Recurrence was also less common
in patients with increased levels of adhesion markers, EGFR
pathway markers, and Rb (total and phosphorylated). For exam-
ple, total and phospho-paxillin (a scaffolding protein) and FAK
(a tyrosine kinase localized at focal adhesions) were lower in
tumor tissue of patients with subsequent disease recurrence. In
addition, p-p130 Cas (another scaffolding protein) was also
lower in patients with recurrence.
The analyses correlating protein levels with clinical
parameters also demonstrated that downregulation of markers
in the energy-sensing AMPK pathway was associated with
worse clinical outcome and with smoking status. Specifically,
lower levels of AMPK and pTSC2 (a downstream target of
AMPK) and higher p-Acetyl-CoA (normally inhibited by
AMPK) were associated with recurrent NSCLC, whereas
TABLE 2. Immunohistochemistry Scores from Paired Samples Demonstrate Higher Caveolin-1 in
Normal Lung and Higher p70S6K and Cyclin B1 in NSCLC Tumors
IHC Scores
Tumor Alveoli
Alveolar
Stroma
Bronchial Epithelium
Cytoplasm Membrane Cytoplasm Membrane Cytoplasm Membrane
Caveolin
Mean 43.1 47.3 24.0 79.0 300 6.6 8.0
Median 20.0 10.0 20.0 80.0 300 5.0 5.0
P70S6K
Mean 63.6 0 48.3
Median 60.0 0 50.0
Cyclin B1
Mean 20.0 0 0
Median 35.2 0 0
IHC, immunohistochemistry; NSCLC, non-small cell lung cancer.
TABLE 3. Protein Markers Associated with Recurrent NSCLC
Recurrence
Mean (log 2) Median (log 2)
pNo Yes No Yes
AMPK pathway proteins AMPK 0.259 0.123 0.302 0.192 0.066
p-Acetyl-CoA 0.385 1.480 0.247 1.365 0.010
pTSC2 0.392 0.169 0.354 0.099 0.003
Adhesion markers STAT3 0.456 0.008 0.260 0.074 0.089
Paxillin 0.719 1.348 0.602 1.426 0.084
p-paxillin (Y118) 0.117 0.195 0.094 0.223 0.075
p-p130 Cas (Y241) 0.023 0.394 0.123 0.377 0.102
EGFR pathway proteins EGFR 0.342 0.278 0.157 0.292 0.009
pAKT (T308) 0.373 0.279 0.327 0.072 0.010
ERK2 0.248 0.236 0.289 0.488 0.014
p-PKCalpha (S657) 0.513 1.105 0.945 1.044 0.112
Total and phospho-Rb Rb 1.011 0.097 0.768 0.301 0.005
p-Rb 1.050 0.148 1.421 0.364 0.119
NSCLC, non-small cell lung cancer.
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higher pTSC2 was associated with longer cause-specific sur-
vival. pAMPK levels were lower in current smokers as
compared with former smokers.
These findings are consistent with previous studies that
have shown that inactivating mutations of the tumor suppressor
LKB1, which is upstream of AMPK, are seen more frequently in
smokers and poorly differentiated NSCLC tumors (versus well
or moderately differentiated tumors)21 and are associated with a
shorter latency, more frequent metastasis, and accelerated pul-
monary tumorigenesis.22 Also, in support of these observations
are preclinical studies that showed that rosiglitazone, an activa-
tor of AMPK, inhibits NSCLC cell line growth and that this
effect can be reversed by siRNA against AMPK.23 Similarly, in
another study, doubling time of A549, a NSCLC cell line with
mutant LKB1, was significantly increased when wild-type
LKB1 was reintroduced.24 In addition, induction of AMPK and
its reciprocal inactivation of the mTOR pathway has been
implicated as a mechanism through which certain chemopreven-
tive agents may act in NSCLC.25 Together, these results suggest
that this pathway may act to suppress tumor growth and/or
malignant spread.
Finally, increased expression of protein markers in the
EGFR pathway was also associated with a lower frequency of
NSCLC recurrence. This is in keeping with clinical studies that
have shown an association between activating mutations in
EGFR and EGFR protein levels and improved clinical out-
comes.26,27 Similar results were observed when analyses of
recurrence and/or cause-specific survival were performed in
stage III/IV patients. However, none of the RPPA markers were
associated with outcome in stage I/II patients. There are at least
two possible explanations for this. First, it is possible that
because stage I/II patients had relatively fewer recurrences, it
was not possible to detect differences between these groups.
Another explanation is that the changes in the tumor that in-
crease the likelihood of recurrence occur later in the develop-
ment/growth of lung cancer and therefore are more likely to be
detected in a more advanced-stage tumor, compared with an
earlier stage tumor. The association of protein markers with
clinical outcome warrants further evaluation both in determining
prognosis and in predicting response to targeted therapies.
Among the four protein markers in the NSCLC signature,
RPPA results for caveolin-1, cyclin B1, and p70S6K were
validated by IHC, which also demonstrated higher caveolin-1 in
normal lung tissue (particularly in alveolar stroma); higher
p70S6K in tumor cells; and cyclin B1 staining exclusive to
tumor cells. The validation of RPPA results by IHC is particu-
larly important for two reasons. First, although RPPA is a
powerful technique for high-throughput screening of large num-
bers of patient samples (up to 1000) in parallel to identify
prognostic or predictive protein biomarkers, it is not the optimal
platform for rapid testing of individual patient samples. In
addition, while RPPA is currently optimized for frozen tissue, it
is much more common for available patient tumor tissue to be
paraffin embedded. Therefore, the correlation of protein levels
quantified in frozen tissue by RPPA with those in paraffin-
embedded tissue by IHC has important clinical implications
because IHC is readily available in clinical pathology laborato-
ries and could be immediately available to assess validated
protein markers in FFPE samples from patients with NSCLC.
Specifically, the validation of RPPA finding by IHC demon-
strates the feasibility of using IHC of FFPE samples (such as
tissue from diagnostic biopsies) to assess protein markers iden-
tified by RPPA in the future for diagnostic purposes or for
treatment selection.
This study demonstrates that proteomic profiling using
RPPA technology can identify dysregulated signaling events
in NSCLC, which is an important step toward identifying
biomarkers and targets that could potentially improve the
outcomes for this and other cancers. Indeed, proteins associ-
ated with PI3K/AKT, MAPK, and Src signaling pathways
were differentially expressed between normal lung and
NSCLC tumors, and a model using only four of the proteins
was capable of distinguishing tumors from normal lung
(p70S6K, cyclin B1, pSrc(Y527), and caveolin-1). The dif-
ferences in levels of potential protein targets between tumor
and normal tissues further supports the concept that molecu-
larly targeted drugs in NSCLC could preferentially target the
tumor tissue with more limited direct effect on normal lung.
In addition, proteomic profiling identified pathways
whose relative expression levels in tumor tissue was associ-
ated with recurrence. In particular, lower levels of the
AMPK, EGFR, and Rb pathways were associated with recur-
rent disease. These studies support the potential of RPPA to
identify differentially expressed protein biomarkers of rele-
vance to lung cancer. These markers, if validated in further
studies, have prognostic implications and may serve as po-
tential drug targets aiding in the development of future
therapeutic strategies.
MATERIALS AND METHODS
Human NSCLC Tumors and Normal Lung
Tissue
Forty-six paired normal lung and NSCLC tumor samples
were obtained from surgical specimens in the M. D. Anderson
Cancer Center Thoracic Tissue Bank (Supplemental Table 1,
http://links.lww.com/JTO/A36). In all cases, histology quality
control was performed by a thoracic pathologist on frozen
tissues. Tumor samples were included in the analysis if the
percentage of malignant cells present in the sample were70%.
Normal lung samples from the same patients were reviewed to
confirm that they contained no malignant cells. Twenty-two of
the tumors were squamous cell carcinomas and 24 were adeno-
carcinomas. The median age of the patients from whom the
tumors had been excised was 67 years (range, 48–81 years); 22
(48%) were women, and 44 (96%) were former or current
smokers. Six (13%) patients had stage IA cancer, 14 (30%) stage
IB, 2 (4%) stage IIA, 13 (28%) stage IIB, 3 (7%) stage IIIA, 6
(13%) stage IIIB, and 2 (4%) stage IV. Nineteen patients (41%)
have subsequently had recurrent disease versus 27 (59%) who
remain without evidence of disease at last contact. Of note, nine
patients without NSCLC recurrence have died of other causes.
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Protein Lysate Preparation and Reverse-Phase
Lysate Array
Protein lysate was prepared from frozen sections of
tumor tissues as previously described.28 Briefly, lysis buffer
(1% Triton X-100, 50 mM HEPES [pH 7.4], 150 mM NaCl,
1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM NaPPi,
10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 mM
Na3VO4, and 10 g/mL aprotinin) was added to the samples
and homogenized, followed by microcentrifugation at 14,000
rpm for 10 minutes.
Cleared supernatants were collected, followed by pro-
tein quantification using the BCA reaction kit (Pierce Bio-
technology, Inc., Rockford, IL). All samples were normalized
to the same starting concentration of 1 mg/ml, which were
then mixed with SDS sample buffer without bromophenol
blue (three parts cell lysate plus one part 4 SDS sample
buffer, which contained 35% glycerol, 8% SDS, 0.25 M
Tris-HCl [pH 6.8]). Before using the 4 SDS buffer, 10%
2-mercaptoethanol was added. The samples were boiled for 5
minutes. Then, the samples (each in duplicate) were serially
diluted from the starting concentration of 1 mg/ml (1:2–1:16)
with dilution buffer (three parts lysis buffer:one part 4 SDS
 2-mercaptoethanol). To each of the diluted samples, an
equal amount of 80% glycerol/2 Ca2- and Mg2-free
phosphate buffered saline solution was added, after which the
diluted samples were transferred to 384-well plates. RPPA
was produced and analyzed as previously described, with
slight modifications.29 Protein lysate arrays were printed on
nitrocellulose-coated glass FAST Slides (GE Whatman, Pis-
cataway, NJ) by a GeneTAC G3 arrayer (Digilab Inc., Hol-
liston, MA) with forty-eight 200-m-diameter pins arranged
in a 4  12 format. Forty-eight grids were printed at each
slide with each grid containing 24 dots. Protein dots were
printed in duplicate with five concentrations. Arrays were
produced in batches of 15, and occasional low-quality arrays
(e.g., with many spot dropouts) were discarded.
Antibody staining of each array was performed at room
temperature using an automated BioGenex autostainer (San
Ramon, CA). Briefly, each array was incubated with a spe-
cific primary antibody, and signal was detected using the
Dako Catalyzed Signal Amplification system according to the
manufacturer’s recommended procedure (DakoCytomation
California, Inc., Carpinteria, CA). The full list of primary
antibodies used in the experiment is outlined in Supplemental
Table 2 (http://links.lww.com/JTO/A36) (inclusive of anti-
body dilutions). Please refer to Tibes et al.11 for details
regarding antibody optimization and validation.
The primary antibodies used in the key signaling path-
ways were extensively validated via Western blots, where band
quality and correlation of protein levels with RPPA were deter-
mined. In brief, the microarray slides were precleared with
Reblot mild stripping solution (Millipore, Billerica, MA) for 5
minutes and then with a general blocking agent (I-block, Foster
City, CA) for 30 minutes. The slides were then blocked for
endogenous peroxidase, avidin, biotin, and protein for 5 minutes
each. After the blocking procedure, the slides were incubated
with primary antibody and secondary antibody (diluted in
DAKO antibody diluent with background-reducing compo-
nents) for 20 minutes each. Signal amplification was accom-
plished by incubating slides with streptavidin-biotin complex,
biotinyl-tyramide, and streptavidin-peroxidase for 15 minutes
each; signal detection was enabled by addition of 3,3-diamino-
benzidine tetrahydrochloride chromogen for 5 minutes. Between
steps, each slide was washed with RPPA TBST (25 mM Tris,
pH 7.6, 300 mM NaCl, 0.1% Tween-20). Spot images were
quantified using imaging analysis with an HP Scanjet 8200
scanner (Hewlett Packard, Palo Alto, CA) with a 256-shade
grayscale at 600 dots per inch.
Forty percent were printed in duplicate in serial dilu-
tions on a single slide, which is then probed with a validated
antibody that recognizes a unique protein or phosphoprotein
and the amount of antibody binding to each sample is quan-
tified. The high capacity of RPPA reduces interassay vari-
ability (as would be seen if each sample was analyzed
independently by Western or similar techniques), with the use
of multiple replicates further increasing quantitation thus
allowing for statistically robust and reproducible comparisons
to be made between samples.
RPPA Data Processing and Statistical Analysis
RPPA data was quantified using a SuperCurve method
that detects changes in protein level by MicroVigene software
(VigeneTech, Carlisle, MA) and an R package developed in
house.30 Briefly, the SuperCurve method generates a common
logistic curve for each antibody by pooling spot intensity data
(obtained from MicroVigene) from all samples on the slide.
Individual dilution series numbers for each sample are then
mapped onto the SuperCurve for quantification. After quan-
tification, data were logarithm transformed (base 2) for fur-
ther processing and analyses. Then, median-control normal-
ization was applied on the dataset. The statistical analyses
were performed using R (version 2.7.0).
Differences in sample loading were adjusted by nor-
malizing each sample using a whole antibody set approach
(available as a script in the R package). This approach, which
is patterned after gene microarray approaches, was chosen
because comparison of actual sample dilutions with single
housekeeping genes (such as -actin or GAPDH) or total
protein stains (such as colloidal gold) and statistical analyses
of relatively invariant proteins (including total Akt, ERK2,
GSK3, and p38) indicated greater variability and less consis-
tency than with the whole set approach.
Before analysis, duplicate samples were averaged. Then,
two-sample t tests were used to compare protein levels between
normal and tumor tissue. Adjusting for multiple testing, we
applied a beta-uniform mixture to model the resulting p values
computed from the test statistic applied and assessed the FDR to
identify significant differentially expressed genes.31,32 In this
investigation, we used an FDR of 1% as cutoff to identify
markers significant differentially expressed between normal and
tumors samples. Next, diagonal linear discrimination analysis
algorithm was applied to build a statistical model for classifica-
tion and prediction. Sensitivity, specificity, positive predictive
value, and negative predictive value were computed from diag-
onal linear discrimination analysis results. Markers selected by
this method were then validated in the test set of 21 paired
samples.
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For correlations between clinicopathological features or
clinical outcomes and protein marker levels, clinical and protein
data from all 46 patients were used. For each protein marker,
tumor levels were first normalized to levels in matched normal
lung tissue from the same patients. Normalized tumor protein
levels were then correlated with clinical features and outcomes
using t test (for gender and N stage), ANOVA (smoking status,
overall pathologic stage, T stage, and recurrence), Cox propor-
tional hazard ratio (cause-specific survival and overall survival),
and linear regression (age).
IHC for Caveolin, p70S6K, and Cyclin B1
Thirty-nine of the 46 paired normal and tumor samples
had FFPE tissue available for testing by IHC. Each case was
represented by three 1-mm diameter tissue cores per tumor
and normal (bronchial epithelium and alveoli) site in a tissue
microarray. Tissue microarray histology sections (5-m
thick) were deparaffinized, hydrated, and heated in a steamer
for 30 minutes with Dako Target Retrieval solution pH 6.0
for antigen retrieval (Dako North America, Inc., Carpinteria,
CA). Peroxide blocking was done with 3% H2O2 in methanol
at room temperature for 15 minutes, followed by 10% fetal
bovine serum in TBST for 30 minutes.
Slides were incubated at room temperature for 90 minutes
with primary antibody against caveolin-1 (BD Transduction
Laboratories, San Jose, CA; dilution 1:500), cyclin B1, and
p70S6K (Cell Signaling, Danvers, MA; dilution 1:300) and then
probed for 30 minutes with the secondary antibody Envision
Dual Link Plus (DAKO, Carpinteria, CA). Staining was devel-
oped with 0.05% DAB (DAKO) and counterstained with hema-
toxylin. Staining was quantified bymultiplying the percentage of
cells staining positive by the intensity of staining (0, 1, 2, or
3). Levels between tissue types in each patient were then
compared by paired t test.
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